Novita Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2010-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.novita-pharm.com
Clinical Trials
3
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Not Applicable
1 (33.3%)Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
Not Applicable
Recruiting
- Conditions
- Platinum-resistant Ovarian Cancer
- Interventions
- Drug: PLD
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- Novita Pharmaceuticals, Inc.
- Target Recruit Count
- 380
- Registration Number
- NCT07109414
- Locations
- 🇺🇸
Trials365, Shreveport, Louisiana, United States
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Phase 1
Recruiting
- Conditions
- Advanced or Metastatic Solid Tumor Malignancies
- Interventions
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Novita Pharmaceuticals, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT05023486
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸University of Arizona - Cancer Center, Tucson, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Phase 1
Completed
- Conditions
- Breast CancerColon CancerOvary CancerAdvanced or Metastatic Treatment-refractory Solid Tumor MalignanciesLung CancerEsophagus CancerLiver CancerPancreas CancerProstate Cancer
- Interventions
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Novita Pharmaceuticals, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT03199586
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸Memorial Sloan Kettering Hospital, New York, New York, United States
News
No news found